RECOMBINANT PROTEIN MARKET ANALYSIS

Recombinant Protein Market, by Product Type (Antibodies, Antigens, Enzymes, Hormones and Others), by Expression System (Microbes, Plant and Animal), by Application ( Drug Discovery and Development, Research Application, Therapeutic Use, Diagnostics, and Others), by End User (Biotechnology and Pharmaceutical Companies, Academic Research Institutes, Contract Research Organizations and Others), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023
Code : CMI1516
Pages :270
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Global Recombinant Protein Market- Driver

Recombinant proteins include recombinant hormones, growth factors, interferon, interleukins, blood clotting factors, tumor necrosis factors, thrombolytic drugs, and enzymes for treating major diseases such as diabetes, dwarfism, congestive heart failure, myocardial infarction, cerebral apoplexy, neutropenia, multiple sclerosis, thrombocytopenia, hepatitis, anemia, Crohn’s disease, rheumatoid arthritis, asthma, cancer, among others, which is expected to drive the market growth over the forecast period. Thus, the increasing prevalence of such diseases is expected to drive the market growth. For instance, according to the data provided by the Breastcancer.org, in March 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer in 2022.

Global Recombinant Protein Market: Restraint

The major factors that can hamper growth of the global recombinant protein market over the forecast period include the high cost of recombinant protein products, high cost involved in its manufacturing and complex process of manufacturing. For instance, according to an article published by MDPI, a publisher of open access scientific journals, in July 2019, the costs of a single clinical trial can vary from US$ 5 million for small, non-controlled orphan drug trials to US$ 350 million for large controlled studies. The median estimate is US$ 19 million.